Dynavax Technologies (NASDAQ:DVAX) was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Monday, February 4th.
Several other equities research analysts also recently weighed in on the company. BidaskClub downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, January 25th. Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Monday, December 31st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $27.00.
NASDAQ DVAX traded up $0.03 during trading on Monday, hitting $9.23. The company’s stock had a trading volume of 1,081,513 shares, compared to its average volume of 698,860. The company has a debt-to-equity ratio of 1.03, a quick ratio of 5.90 and a current ratio of 6.29. The company has a market cap of $656.37 million, a PE ratio of -3.62 and a beta of 0.79. Dynavax Technologies has a fifty-two week low of $7.85 and a fifty-two week high of $22.80.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). The business had revenue of $3.90 million during the quarter, compared to analyst estimates of $3.43 million. Dynavax Technologies had a negative return on equity of 97.79% and a negative net margin of 5,044.85%. Dynavax Technologies’s revenue was up 18471.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.45) EPS. On average, sell-side analysts predict that Dynavax Technologies will post -1.79 earnings per share for the current fiscal year.
In related news, SVP Robert Coffman sold 63,202 shares of Dynavax Technologies stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $9.03, for a total transaction of $570,714.06. Following the completion of the sale, the senior vice president now owns 86,268 shares of the company’s stock, valued at $779,000.04. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP David Louis Johnson sold 20,765 shares of Dynavax Technologies stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $9.03, for a total value of $187,507.95. Following the transaction, the vice president now owns 52,786 shares of the company’s stock, valued at $476,657.58. The disclosure for this sale can be found here. Insiders have sold 121,411 shares of company stock valued at $1,096,031 in the last ninety days. Corporate insiders own 3.47% of the company’s stock.
A number of hedge funds have recently made changes to their positions in DVAX. BlackRock Inc. raised its position in Dynavax Technologies by 5.2% during the second quarter. BlackRock Inc. now owns 4,067,094 shares of the biopharmaceutical company’s stock valued at $62,023,000 after acquiring an additional 202,306 shares in the last quarter. Raymond James & Associates purchased a new stake in shares of Dynavax Technologies in the second quarter valued at approximately $525,000. Bank of America Corp DE increased its position in shares of Dynavax Technologies by 670.2% in the second quarter. Bank of America Corp DE now owns 279,423 shares of the biopharmaceutical company’s stock valued at $4,261,000 after buying an additional 243,142 shares in the last quarter. Millennium Management LLC increased its position in shares of Dynavax Technologies by 184.6% in the second quarter. Millennium Management LLC now owns 129,902 shares of the biopharmaceutical company’s stock valued at $1,981,000 after buying an additional 84,254 shares in the last quarter. Finally, Northern Trust Corp increased its position in shares of Dynavax Technologies by 9.8% in the second quarter. Northern Trust Corp now owns 750,442 shares of the biopharmaceutical company’s stock valued at $11,445,000 after buying an additional 66,677 shares in the last quarter. Institutional investors own 75.53% of the company’s stock.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Featured Article: Exchange-Traded Funds (ETFs)
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.